News | Proton Therapy | September 20, 2017

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients

ProCure recognizes patients treated with proton radiation in honor of Prostate Cancer Awareness Month

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients

September 20, 2017 — ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first group of prostate cancer patients treated at the center after it opened in March 2012. At the time, it was the 10th proton therapy treatment center in the United States, welcoming patients with various cancer types that could benefit from this advanced form of radiation therapy.

Prostate cancer is the most frequently diagnosed cancer among men in the United States other than skin cancer, according to the American Cancer Society, and about one in seven men will be diagnosed at some point throughout his lifetime. September is Prostate Cancer Awareness Month and ProCure Proton Therapy Center New Jersey urges men of all ages to learn about the factors that can increase their chances of getting prostate cancer and familiarize themselves with treatment options that are available to them.

Over the past five years, ProCure Proton Therapy Center New Jersey has treated over 3,000 patients and embraced a culture of patient-centric services where patient needs and comfort are paramount. Patients Bob Jones and Peter Van Drumpt were among an early group of prostate cancer patients to be treated at the Center. Like many patients who walk through ProCure’s doors, these men were drawn to the Center for its innovative technology and the staff’s passion for the well-being of patients. Now, five years later, they remain prostate cancer-free and maintain their quality of life.

“Looking back at the time I spent at ProCure, I’m extremely happy I made the decision to undergo proton therapy for prostate cancer treatment. Five years later, I’m still reaping the benefits from proton therapy and, because of my experience at the Center, I’m now an avid patient ambassador. It’s my hope that I can help other men in the same way that ProCure has helped me,” shared Jones.

Van Drumpt also recalls that while determining which treatment was best for him, the process was overwhelming. However, discussing his options with ProCure physicians and former patients was essential to making his important health decision. “It was tough deciding where to begin since there were so many resources online about prostate cancer treatment options. It was a relief to have the support of ProCure team members as well as the ability to gain helpful insight from patient ambassadors on their experience with the treatment as I embarked on my own journey.” Van Drumpt shared.

“Most men who are faced with a prostate cancer diagnosis struggle in the beginning with the wealth of information that is presented to them. Our team goes above and beyond to ensure patients have the resources they need every step of the way,” shared Henry Tsai, M.D., radiation oncologist at ProCure. He continued, “Proton therapy is a safe and effective treatment option for men with prostate cancer who are concerned about the potential side effects associated with other treatment options.”

In honor of Prostate Cancer Awareness Month, ProCure Proton Therapy Center New Jersey encourages men to be cognizant of what may put them at risk for prostate cancer. Factors such as being older than 50 years of age, having an immediate blood relative who had prostate cancer, or being of African American descent can put men at higher risk for getting prostate cancer. The Center offers an infographic on prostate cancer and proton therapy that can serve as a resource to help men take charge of their healthcare decisions that can be downloaded here.

For more information: www.procure.com/new-jersey-explore

Related Content

Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer
A special issue of the Journal of Medical Imaging and Radiation Sciences features stories about the interpersonal skills beyond the technical aspects to care for and guide patients through medical imaging and radiation therapy procedures

Image courtesy of Canon

News | Patient Engagement | August 11, 2020
August 11, 2020 — "I went into the MRI
Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...